English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective:  This study assessed the methylation of peripheral  NCAPH2  in individuals with subjective cognitive decline (SCD), identified its correlation with the hippocampal volume, and explored whether the correlation is influenced by apolipoprotein E ε4 (APOE ε4) status.   Methods:  Cognitively normal controls (NCs,  n  = 56), individuals with SCD ( n  = 81), and patients with objective cognitive impairment (OCI,  n  = 51) were included from the Sino Longitudinal Study on Cognitive Decline (NCT03370744). All participants completed neuropsychological assessments, blood tests, and structural MRI.  NCAPH2  methylation was compared according to the diagnostic and APOE ε4 status. Partial correlation analysis was conducted to assess the correlations between the hippocampal volume, cognitive tests, and the  NCAPH2  methylation levels.   Results:  Individuals with SCD and patients with OCI showed significantly lower levels of  NCAPH2  methylation than NCs, which were independent of the APOE ε4 status. The  NCAPH2  methylation levels and the hippocampal volumes were positively correlated in the SCD  APOE  ε4 non-carriers but not in the OCI group. No association was found between the  NCAPH2  methylation levels and the cognitive function.   Conclusion:  Abnormal changes in blood  NCAPH2  methylation were found to occur in SCD, indicating its potential to be used as a useful peripheral biomarker in the early stage of Alzheimer's disease screening.

Blood NCAPH2 Methylation Is Associated With Hippocampal Volume in Subjective Cognitive Decline With Apolipoprotein E ε4 Non-carriers